PATENT CLAIM ANALYSIS

Application Number: 15934526
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-09
Patent Classification: ["530", "387100"]

Abstract:
This invention relates to humanized antibodies that selectively bind the 31.1 epitope on the A33 protein differentially expressed in cancers including, lung cancer, ovarian cancer, pancreas cancer, breast cancer, and colon cancer, and diagnostic and therapeutic usages.

Claim (Index 21):
The method of  claim 20 , wherein the presence of said 31.1 epitope is indicative of a carcinoma, optionally lung, breast, pancreas, uterine, esophageal, colorectal, or liver cancer.

Metadata:
- Claim Count in Document: 56.0
- Percentile: 90.0
- Lexical Diversity: 1.375
- Patent Class: 530.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14655982', '12751791', '15510545', '14460871', '11715307']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7393991338253638
- 35 USC 102 Novelty (BERT): 0.5712515203162459
- Combined Prediction Score: 0.7225843724744521
- Mean Citation Score: 431.43559000000016
- Max Citation Score: 566.4305
- Similarity Product: 344.8329927634001

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test